WO2019060687A1 - Procédé de détermination de globules rouges foetaux dans une circulation maternelle par cytométrie de flux - Google Patents

Procédé de détermination de globules rouges foetaux dans une circulation maternelle par cytométrie de flux Download PDF

Info

Publication number
WO2019060687A1
WO2019060687A1 PCT/US2018/052174 US2018052174W WO2019060687A1 WO 2019060687 A1 WO2019060687 A1 WO 2019060687A1 US 2018052174 W US2018052174 W US 2018052174W WO 2019060687 A1 WO2019060687 A1 WO 2019060687A1
Authority
WO
WIPO (PCT)
Prior art keywords
hbf
binding agent
hba
agent
binding
Prior art date
Application number
PCT/US2018/052174
Other languages
English (en)
Inventor
Fabrice Malergue
Andreas Van Agthoven
Jean Marc BUSNEL
Original Assignee
Beckman Coulter, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckman Coulter, Inc. filed Critical Beckman Coulter, Inc.
Publication of WO2019060687A1 publication Critical patent/WO2019060687A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Definitions

  • This invention relates to compositions and methods for determining fetal red blood cells (RBCs) in maternal circulation using flow cytometry.
  • RBCs fetal red blood cells
  • Fetal -maternal hemorrhage is the loss of fetal blood cells into the maternal circulation. Normally the maternal circulation and the fetal circulation are kept from direct contact with each other, with gas and nutrient exchange taking place across a membrane in the placenta. FMH occurs when this membrane ceases to function as a barrier and fetal cells come in contact with and enter the maternal vessels; loss of an excess of fetal blood to the maternal circulation may result in significant morbidity and mortality to the fetus. In addition, loss of fetal blood to maternal circulation may stimulate antibody production in the pregnant female to the fetal RBCs and may have detrimental effect on the newborn, for example, causing the Rhesus disease. Therefore it is important to monitor the amount of fetal blood in the maternal blood during pregnancy.
  • FMH detection methods are based on the fact that fetal RBCs have a unique hemoglobin isoform, HbF, which is different from the hemoglobin isoform, HbA, in adults.
  • the conventional assay of FMH detection is the Kleihauer assay, which involves preparing a blood smear from the maternal blood and expose the smear to an acid bath. The acid exposure removes adult hemoglobin HbA, but not fetal hemoglobin (HbF) from the respective RBCs. This allows fetal RBCs to be distinguished by color under microscope, for example, the fetal cells may appear rose-pink, while adult RBCs are only seen as "ghosts" after the staining.
  • This disclosure provides a method of detecting fetal RBCs in a blood sample from a patient, wherein the blood sample is suspected of comprising fetal blood cells, comprising: contacting a blood sample with an HbF-binding agent and an HbA-binding agent to form a stained blood sample, and detecting fetal RBCs in the stained blood sample, wherein the fetal RBCs bind to the HbF-binding agent but not the HbA-binding agent.
  • the method further comprises contacting the blood sample with a permeabilizing agent before contacting the blood sample with the HbF-binding agent and the HbA-binding agent.
  • the HbA-binding agent binds to HbAlc.
  • the patient is a pregnant female, e.g., a pregnant female human.
  • the method further comprises determining the adult patient has fetal-maternal hemorrhage (FMH) when the presence of fetal RBCs in the blood sample are detected.
  • FMH fetal-maternal hemorrhage
  • the HbF-binding agent is conjugated to a first label and the HbA or HbAlc-binding agent is conjugated to a second label, wherein the first label and the second label are distinguishable, and wherein the measuring the binding of the HbF-binding agent to the RBCs in the stained blood is by detecting the signal from the first label and measuring the binding of the HbA or HbAlc-binding agent to the RBCs in the stained blood sample is by detecting the signal from the second label.
  • the step of detecting fetal RBCs includes incubating the sample with a first detection agent that specifically binds to the HbF-binding agent and a second detection agent that specifically binds to the HbA or HbAlc-binding agent, wherein the binding of the first detection agent to HbF and the binding of the second detection agent to HbAlc are detectable and distinguishable.
  • the blood sample is fixed by a fixing agent before contacting the permeabilizing agent. In some cases, the sample are permeabilized and subsequently stained without being fixed.
  • the HbF-binding agent is an antibody. In some embodiments, the HbF-binding agent is an antibody.
  • the HbA or HbAlc-binding agent is an antibody.
  • the detecting fetal RBCs is by flow cytometry.
  • the concentration of the HbF antibody and/or the concentration of the Hbl Ac antibody is in the range of 0.5-10 ⁇ g/ml. In some embodiments, the concentration of the HbF antibody and/or the
  • concentration of the Hbl Ac antibody is 2.5 ⁇ g/ml.
  • the sample is first diluted with a saline solution before contacting the permeabilizing agent.
  • the sample is diluted 10 to 100 fold before permeabilization.
  • the cells are permeabilized for 2-10 minutes.
  • the step of contacting the sample with HbF-binding agent and a HbA or HbAlc-binding agent further comprises incubating the sample with the HbF antibody and the Hbl Ac antibody for 5-30 minutes.
  • the binding of the HbF antibody and the HbAlc antibody is in the presence of 1-10 mg/ml a blocker protein, such as BSA.
  • the fixing agent contains an aliphatic aldehyde.
  • the permeabilizing agent contains a zwitter-ionic detergent.
  • the permeabilizing agent contains a N-acyl sarcosine or a salt thereof represented by the following molecular structure: Rl-CO-N(CH3)CH2COOXi, wherein Ri is an alkyl or alkylene group having 8 to 18 carbon atoms, and Xi is H, Na + , or K + ; and said permeabilizing reagent has a pH between 4 and 6 and a low ionic strength defined by conductivity of less than 9 mS/cm.
  • kits comprising a labeled HbAlc-binding agent and a labeled HbF-binding agent.
  • the labeled HbAlc-binding agent and the labeled HbF-binding agent are comprised in the same vessel.
  • the kit may further comprise one or more saline solutions, a fixing agent, a permeabilizing agent, and/or a staining solution.
  • the kit further comprising: a first vessel, wherein the first tube includes the saline solution, a second vessel, wherein the second vessel includes the fixing and permeabilizing agent, and a third vessel, wherein the third vessel contains the staining buffer.
  • the third vessel contains the a first fluor coupled to an antibody directed against HbF and a second fluor coupled to an antibody directed against HbAlc.
  • the contents in one or more of the vessels in the kit are in dry form.
  • FIGs. 1A and IB show the results of a flow cytometry analysis of a whole blood sample that have been stained with an HbAlc antibody and an HbF antibody.
  • FIG. 1C shows the results of a flow cytometry analyiss of a mixed blood sample that contains a minor fraction of cord blood and whole blood sample. The mixed blood sample was also stained with an HbAlc and an HbF antibody.
  • This invention provides compositions, kits, and methods using the HbAlc antibody and HbF antibody to stain blood samples from pregnant females in flow cytometry analysis to detect presence of fetal RBCs with desired sensitivity and specificity.
  • a labeled molecule refers to a molecule that is associated with a detectable label and can be identified using methods known in the art, e.g., in flow cytometry.
  • the molecule is labeled by a direct linkage to a detectable label.
  • the molecule is labeled by indirect association with a detectable label.
  • the molecule is an antibody, e.g., the HbA or HbAlc antibody and the HbF antibody.
  • a phrase such as "HbF antibody” should be understood to mean an antibody with specificity to HbF. Under appropriate binding conditions, an HbF antibody is capable of binding to HbF.
  • an HbAlc antibody is capable of binding to HbAlc and an HbA antibody is capable of binding to HbA.
  • the term "patient" refers to a human or animal.
  • the animal subject may be a mammal, a primate (e.g., a monkey), a livestock animal (e.g., a horse, a cow, a sheep, a pig, or a goat), a companion animal (e.g., a dog, a cat), a laboratory test animal (e.g., a mouse, a rat, a guinea pig, a bird), an animal of veterinary significance, or an animal of economic significance.
  • the patient is a pregnant female.
  • a fetus is not a patient within the meaning of this disclosure.
  • binding agent refers to a molecule that can specifically and selectively bind to a second (i.e., different) molecule of interest.
  • a binding agent can be a small molecule compound or a protein, e.g., an antibody.
  • an HbA-binding agent refers to a binding agent that specifically and selectively binds to either Fib A or to HbAlc.
  • target refers to a molecule, compound or cell that is being detected.
  • the target can be detected via its interaction with a binding agent.
  • target may refer to a protein or peptide of interest, i.e., HbF, Hb A and/or HbAlc.
  • antibody as used herein also includes a full-length antibody as well as an "antigen-binding portion" of an antibody.
  • antigen-binding portion refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., HbF or HbA or HbAlc).
  • binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341 :544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR).
  • a Fab fragment a monovalent fragment consisting of the VL, VH, CL and CHI domains
  • F(ab')2 fragment a bivalent fragment comprising two Fab fragments linked by a
  • the two domains of the Fv fragment, VL and VH are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85 :5879-5883; and Osbourn et al. 1998, Nature Biotechnology 16: 778).
  • scFv single chain Fv
  • Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody.
  • Any VH and VL sequences of specific scFv can be linked to human immunoglobulin constant region cDNA or genomic sequences, in order to generate expression vectors encoding complete IgG molecules or other isotypes.
  • VH and VI can also be used in the generation of Fab, Fv or other fragments of immunoglobulins using either protein chemistry or recombinant DNA technology.
  • Other forms of single chain antibodies, such as diabodies are also encompassed.
  • Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2: 1121-1123).
  • Antibodies may be polyclonal or monoclonal; xenogeneic, allogeneic, or syngeneic; or modified forms thereof, e.g. humanized, chimeric, etc. Antibodies of the invention bind specifically or substantially specifically to one or more proteins or modified proteins, such as glycated proteins.
  • the term "monoclonal antibodies” refer to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of an antigen
  • polyclonal antibodies and “polyclonal antibody composition” refer to a population of antibody molecules that contain multiple species of antigen binding sites capable of interacting with a particular antigen.
  • a monoclonal antibody composition typically displays a single binding affinity for a particular antigen with which it immunoreacts.
  • the invention may be used to detect fetal RBCs in a blood sample from a patient, wherein the blood sample is suspected of comprising fetal blood.
  • the blood sample can be obtained from a human or from another animal.
  • the examples detailed below refer to human blood samples and to antibodies directed to human antigens, such as human HbF and human HbA or HbAlc.
  • substitution of the antibodies by others directed against corresponding proteins from other species or use of antibodies against human HbF or human HbA or HbAlc, where there is appreciable cross- reactivity with the respective proteins in another species
  • the blood sample comprises whole blood.
  • the blood sample comprises the whole blood and an anticoagulant, e.g., ethylene diamine tetra acetic acid (EDTA) or heparin.
  • EDTA ethylene diamine tetra acetic acid
  • FMH fetal -maternal hemorrhage
  • FMH is the loss of fetal blood cells into the maternal circulation. It takes place in normal pregnancies as well as when there are obstetric or trauma-related complications to pregnancy. FMH may be caused by trauma, by placental abruption or may be spontaneous with no cause found. FMH accompanied with a loss in excess of e.g., 30 ml of fetal blood to maternal circulation may result in significant morbidity and mortality to the fetus.
  • Detecting of FMH can aid important decision-making processes during a female's pregnancy: for example, if ongoing and rapid hemorrhage is occurring then immediate delivery of the fetus may be desired if the fetus is sufficiently developed; and if the hemorrhage has already occurred and now stopped, an in utero transfusion of red cells to the fetus may be recommended.
  • HbF is the main oxygen transport protein in the human fetus during the last seven months of development in the uterus. HbF persists in the newborn until roughly 6 months old, when HbF is nearly completely replaced by adult hemoglobin (HbA). Fetal hemoglobin differs most from adult hemoglobin in that it is able to bind oxygen with greater affinity than the adult form, giving the developing fetus better access to oxygen from the mother's bloodstream.
  • Adult RBCs typically do not express HbF, although in some cases, a certain percentage of adult RBCs may express HbF, for example, when the patient carries certain diseases such as thalassemia, or when the patient is taking certain medication during treatment of a disease, which reactivates HbF expression. HbF is expressed intracellularly.
  • HbA is one form of hemoglobin found in adult RBCs. Like HbF, HbA is also expressed inside the RBCs. HbA can bind to glucose, producing any of a number of glycated forms, of which HbAlc has most clinical history;HbAlc levels are routinely monitored to control blood sugar levels. Importantly, fetal RBCs do not express HbA and hence also lack glycated HbA, including HbAlc. The present invention is based on fetal RBCs' expression of HbF but not HbA. HbAlc and other glycated forms of HbA are consequently absent in fetal RBCs. Thus, fetal RBCs could be detected by identifying whether a given cell includes HbF or a variant of HbA (including HbAlc or unglycated HbA). Fetal cells include HbF but lack HbA variants.
  • the method employs HbF-binding agents and HbA or HblAc (or other glycated HbA) binding agents to detect fetal RBCs; fetal RBCs bind to HbF-binding agents but not HbA or Hbl Ac-binding agents; adult RBCs would bind to HbA or Hb l Ac-binding agents but (usually) not to HbF-binding agent.
  • HbF-binding agents and HbA or HblAc (or other glycated HbA) binding agents to detect fetal RBCs
  • fetal RBCs bind to HbF-binding agents but not HbA or Hbl Ac-binding agents
  • adult RBCs would bind to HbA or Hb l Ac-binding agents but (usually) not to HbF-binding agent.
  • a binding agent used herein can be any molecule, i.e., a small molecule, sugars, oligosaccharides, lipids, peptides, peptidomimetics, nucleoside analog, organic compounds and the like, so long as it can specifically bind to HbF or HbA or HbAlc.
  • the binding agents are antibodies.
  • Antibodies used for detecting fetal RBCs include any antibodies that recognize HbF and any antibodies that recognize HbA, or glycated HbA, such as HbAlc.
  • Antibodies that can be produced by immunizing animal with the HbF or HbA or HbAlc protein or a portion thereof and produced and purified using methods are well known in the art. See, for example, Kohler and Milstein, Nature 256: 495 (1975), and Coligan et al. (eds.), CURRENT PROTOCOLS IN IMMUNOLOGY, VOL. 1, pages 2.5.1-2.6.7 (John Wiley & Sons 1991).
  • HbF, HbA, and HbAlc antibodies are also commercially available, for example, from Biocompare, South San Francisco, Calif. These antibodies can also be used in the methods and kits disclosed herein.
  • the present invention uses labels that can be detected, the signals of these labels can be used to indicate the binding between the HbF-binding agent, the HbA or glycated HbA (such as HbAlc)-binding agent and the RBCs.
  • a label used in the invention can be any label that can be detected, e.g., by flow cytometry.
  • Non-limiting examples of the labels include those listed in Table 1, below.
  • Table 1 Some exemplary labels used to label antibodies.
  • Quantum dots are fluorescent nanocrystals that have a wide absorption spectrum and so can be excited by a range of different wavelengths. Their emission wavelengths also vary and may range from blue to deep red.
  • Mass labels are atoms or molecular fragments having a characteristic mass or ionization pattern detectable by, for example, a mass spectrometer. One skilled in the art can readily determine which types of labels to use based on the purpose and nature of the assay.
  • the methods and kits disclosed herein use a first label for detecting the binding of the HbF-binding agent to the RBCs and a second label for detecting the binding of the HbA or HbAlc-binding agent to the RBCs and the first and second labels are distinguishable.
  • the distinction is detected in flow cytometry based on the difference in excitation and emission wavelength of the labels.
  • One of ordinary skill in the art can readily determine combinations of two labels that are suitable for use in detecting and distinguishing between the binding of HbF-binding agent to the RBCs and binding of HbAlc-binding agent to the RBCs in the same sample by flow cytometry analysis.
  • the first label is Alexa-488 and the second label is Alexa-647.
  • the labels that are used to conjugated the HbF-binding agent and the HbA or HbAlc-binding agent can also be switched, for example, in some cases, the first label is Alexa-647 and the second label is Alexa-488.
  • the present disclosure provides a method of detecting fetal RBCs from a blood sample from a patient when the blood sample is suspected of comprising fetal blood cells.
  • the blood sample may be drawn from the patient and tested immediately.
  • an anticoagulant e.g., ethylene diamine tetra-acetic acid (EDTA) or heparin is added to the blood sample before testing.
  • EDTA ethylene diamine tetra-acetic acid
  • One advantage of the method disclosed herein is that the amount of the blood sample needed for the test can be very small, typically no greater than 200 ⁇ , no greater than 100 ⁇ , no greater than 50 ⁇ , no greater than 20 ⁇ , or no greater than 10 ⁇ .
  • the whole blood sample obtained from the patient is first diluted with a saline solution.
  • saline solutions include phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • the volume ratio between the blood and saline solution may range from 1 : 10 to 1 : 100, e.g., from 1 :20 to 1 :50, or 1 :40.
  • the method of detecting fetal RBCs in a blood sample from a patient comprises contacting the blood sample with a permeabilizing agent.
  • the permeabilizing agent contains a detergent, for example, a zwitter-ionic detergent.
  • the detergent may be an anionic detergent, for example, sodium dioxycholate or N-lauryl sarcoside.
  • the detergent is sodium dodecyl sulphate.
  • the concentration of detergent can be between 0.001% and 10%, e.g., between 0.01 and 5%.
  • the permeabilizing agent contains approximately 0.03% of sodium dodecyl sulphate.
  • the permeabilizing agent comprises N-acyl sarcosine or a salt thereof that is represented by the molecular structure of Ri-CO- N(CH3)CH2COOXi, wherein the Ri is an alkyl or alkylene group having 8 to 18 carbon atoms, and Xi is H, Na + , or K + .
  • the permeabilizing agent has a pH between 3-8.
  • the permeabilizing agent has an acidic pH, e.g., a pH between 4 and 6.
  • the permeabilizing agent may have a low ionic strength defined by conductivity of less than 9 mS/cm.
  • the permeabilizing agent may further comprises an oligosaccharide, e.g., trehalose.
  • an oligosaccharide e.g., trehalose.
  • the permeabilizing agent that can be used for the invention is also substantially described in US 7,541,190 and US 6,534,279, the entire contents of the patents are hereby incorporated by reference.
  • the permeabilizing agents used herein may cause precipitation of the hemoglobin in RBCs while the cell membranes are being permeabilized, thus advantageously dispensing the need for a separate fixation step.
  • the sample can be permeabilized and stained without being fixed.
  • the sample is fixed before permeabilization.
  • the claimed method may avoid the need for a neutralization step after fixation, because the amount of fixative is relatively low and the fixing agent in the mixture is further diluted by the staining solution (see below) by at least 2 fold, e.g., at least 2.5 fold, or at least 3 fold. Therefore in some embodiments, the method does not comprise a neutralization step.
  • Fixing agents that can be used in the invention include but are not limited to an aliphatic aldehyde, preferably one containing C1-C5.
  • Non-limiting examples of fixing agents includes formaldehyde, paraformaldehyde, and glutaraldehyde.
  • the sample is fixed with a solution comprises an aliphatic aldehyde, e.g., formaldehyde, in a concentration of between 0.05% and 0.5% (v/v), e.g., between 0.06% and 0.4%, between 0.1% and 0.3%, or between 0.2% and 0.5%.
  • the duration of the fixation and/or permeabilization may vary. In some cases, the fixation or the permeabilization may last 1-30 min, e.g., 2-20 min, 2-10 min, 3-10 min, or about 4 min. In some cases, fixation is performed before permeabilization.
  • the sample that has been permeabilized and/or fixed are then contacted with the HbF-binding agent and the HbA or HbAlc-binding agent.
  • Incubating the sample with directly or indirectly labeled binding agents is commonly referred to as staining.
  • the contacting is performed by incubating the permeabilized and/or fixed sample in a staining solution containing one or both binding agents and one or more blocker proteins.
  • Blocker proteins are those that can reduce non-specific binding, e.g., bovine serum albumin (BSA) or fetal bovine serum (FBS).
  • the staining solution contains bovine serum albumin at a concentration of 1-100 mg/ml, e.g., 1-70 mg/ml, 2-50 mg/ml, 1-10 mg/ml, 2-8 mg/ml, or about 5 mg/ml.
  • the permeabilized sample is contacted with both the HbF-binding agent and the HbA or HbAlc-binding agent simultaneously.
  • the permeabilized sample is first contacted with the HbF- binding agent and then with the HbAlc-binding agent, or vice versa.
  • the binding of the HbF-binding agent and of the HbA or HbAlc-binding agent in the permeabilized RBCs can be detected and differentiated through the two distinguishable labels.
  • the labels are directly conjugated to the HbF and/or HbA or HbAlc- binding agents.
  • the labels are conjugated to detection agents that specifically recognize the HbF-binding agent and the HbA or HbAlc-binding agent, respectfully.
  • the concentration of the binding agents used in the assay can be any amount that is sufficient to produce positive signal and avoid non-specific staining.
  • the binding agents are an HbF antibody and an HbAlc antibody.
  • the concentration of the HbF antibody or the HbAlc antibody is in the range of 0.5-10 ⁇ g/ml, e.g., 1-8 ⁇ g/ml, 1-5 ⁇ g/ml, 2-4 ⁇ g/ml, e.g., 2.5 ⁇ g/ml.
  • the time period of staining the sample with the antibodies may vary, depending on the concentration of the antibody and the affinity of the antibody to the corresponding antigen. In general, the staining may last 5-60 min, e.g., 5-30 min or 10-15 minutes.
  • a saline solution that contains a fixing agent is added to the stained sample before loading the sample to a device to detect signals from the labels.
  • the saline solution that is used to dilute the blood sample, the staining buffer, and/or antibodies are contained in respective vessels provided for the testing in dry form, and these contents of the vessels are reconstituted with water or buffer to form solutions as described above before the assay.
  • the signals from the labels which indicate whether a red blood cell binds to the HbF-binding agent or the HbA, or (glycated HbA, such as) Hbl Ac-binding agent, can be detected by a variety of methods, including but not limited to, imaging methods (e.g., fluorescent microscopy) and flow cytometry.
  • imaging methods e.g., fluorescent microscopy
  • flow cytometers include Gallios, CytoFLEX, and Navios from Beckman Coulter, Inc.
  • the present invention also provides a kit comprising an HbA or HbAlc-binding agent and an HbF-binding agent.
  • an HbA or HbAlc-binding agent and an HbF-binding agent are labeled.
  • the kit comprises a mixture of an HbAlc-binding agent and a HbF-binding agent.
  • the kit may also comprise one or more additional components selected from the group consisting of a saline solution, a permeabilizing agent, and a fixing agent.
  • the HbAlc-binding agent and/or the HbF-binding agent is an antibody that can bind to the HbAlc and/or HbF, respectively.
  • the kit may also contain vessels for carrying out the method steps as described above.
  • the kit comprises an HbAlc-binding agent, an HbF-binding agent, a first vessel that contains the saline solution, a second vessel that contains the fixing and permeabilizing agent, and a third vessel that contains the staining buffer.
  • the third vessel also contains the HbF-binding agent and the HbAlc-binding agent.
  • kits comprising components for the methods of detecting fetal RBCs that are present in dry form in the vessels have greater the stability and are more convenient during storage.
  • composition of the permeabilizing agent contains:
  • permeabilizing agent To prepare the permeabilizing agent, deionized water was used to dissolve the components listed in the Table above. The solution was then filtered through a sterile nylon filter of 0.22 ⁇ pore size. The permeabilizing agent had a conductivity of 0.99 mS/cm and osmolality of 268 mOsm/Kg H2O.
  • tubes were provided. 400 ⁇ PBS was added to tube A, and 200 ⁇ of 5 mg/ml BSA, 0.5 ⁇ g of HbF antibody, and 0.5 ⁇ g of HbAlc antibody were added to tube C. 200 ⁇ of the permeabilizing agent described above was added to tube B.
  • the contents of the tubes can be dried and reconstituted with deionized water prior to use.
  • Cord blood containing fetal blood was collected from a pregnant female patient at delivery of her newborn. A small amount of the cord blood containing fetal blood was added to a whole blood sample so that the mixed blood sample contained 0.03% of cord blood. 10 ⁇ of mixed blood sample was added to tube A as prepared above. The tube was vortexed twice, each time 1 second, to mix the blood sample with the solution in tube A. 10 ⁇ of the mixture in tube A was then added to tube B and the content of the tube B was mixed by vortexing twice immediately, 1 second each time. The mixture in tube B was incubated for about 4 minutes. 100 ⁇ of mixture in tube B was then added to tube C.
  • the content in tube C was then mixed by vortexing twice immediately, each time 1 second, followed by incubating the mixture for 10-15 min.
  • 200 ⁇ of a flow solution containing lxPBS and 0.17 M formaldehyde was added to tube C, and the mixture in tube C was vortexed and then analyzed using a flow cytometer.
  • An aliquot of the whole blood sample (without cord blood) is treated in the same manner and serves as a control.
  • the HbF signal from the cells was detected on the FL1 channel and the Fib Ale signal from the cells was detected on the FL6 channel.
  • FIGs. 1A and IB show the results of the whole blood sample and FIG. 1C shows the results of the mixed blood sample by flow cytometry analysis.
  • the data tables below the plots in FIG. IB and 1C show the number and percentages of cells being detected in respective plots.
  • FIG. 1A is a forward scatter and side scatter plot of the whole blood sample.
  • FIG. IB shows that, as expected, the whole blood sample (the control) essentially did not contain cells having high expression levels of HbF but low expression levels of HbAlc, as indicated by that out of a total of 200,295 cells, only one (1) cell was detected in the boxed region adjacent the vertically-oriented axis - a 0.00%.
  • 1C shows a small population of cells in the mixed blood sample (81 out of a total of 200,326 cells), which were visible in the boxed region adjacent the vertically-oriented axis, had high expression levels of HbF but very low or no expression of HbAlc— these cells were fetal RBCs.
  • a large population of cells did not express HbF but expressed HbAlc to various degrees— these cells were adult RBCs.
  • the amount of the detected fetal RBCs accounts for about 0.04% of the total RBCs, indicating the method is accurate in detecting fetal RBCs in the blood sample that contains both adult blood and a minor fraction of fetal blood (0.03%) of the cord blood added to the whole blood before detection).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés d'identification de globules rouges foetaux dans un échantillon sanguin qui est suspecté de contenir du sang foetal. L'invention concerne également des kits qui peuvent être utilisés à cet effet.
PCT/US2018/052174 2017-09-21 2018-09-21 Procédé de détermination de globules rouges foetaux dans une circulation maternelle par cytométrie de flux WO2019060687A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762561515P 2017-09-21 2017-09-21
US62/561,515 2017-09-21

Publications (1)

Publication Number Publication Date
WO2019060687A1 true WO2019060687A1 (fr) 2019-03-28

Family

ID=63858078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/052174 WO2019060687A1 (fr) 2017-09-21 2018-09-21 Procédé de détermination de globules rouges foetaux dans une circulation maternelle par cytométrie de flux

Country Status (1)

Country Link
WO (1) WO2019060687A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003431A1 (fr) * 1993-07-19 1995-02-02 Aprogenex, Inc. Enrichissement et identification de cellules f×tales dans du sang maternel destinees a une hybridation in situ
WO2003021275A1 (fr) * 2001-09-04 2003-03-13 Iq Corporation B.V. Determination et quantification des populations de globules rouges dans des echantillons
US6534279B1 (en) 1998-07-09 2003-03-18 Immunotech Reagent and method for the permeabilization and identification of erythrocytes
US7541190B2 (en) 2005-02-07 2009-06-02 Beckman Coulter, Inc. Method of measurement of cellular hemoglobin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003431A1 (fr) * 1993-07-19 1995-02-02 Aprogenex, Inc. Enrichissement et identification de cellules f×tales dans du sang maternel destinees a une hybridation in situ
US6534279B1 (en) 1998-07-09 2003-03-18 Immunotech Reagent and method for the permeabilization and identification of erythrocytes
WO2003021275A1 (fr) * 2001-09-04 2003-03-13 Iq Corporation B.V. Determination et quantification des populations de globules rouges dans des echantillons
US7541190B2 (en) 2005-02-07 2009-06-02 Beckman Coulter, Inc. Method of measurement of cellular hemoglobin

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"CURRENT PROTOCOLS IN IMMUNOLOGY", vol. 1, 1991, JOHN WILEY & SONS
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BOHMER RALPH M ET AL: "Fetal cell isolation from maternal blood cultures by flow cytometric hemoglobin profiles. Results of a preliminary clinical trial", FETAL DIAGNOSIS AND THER, KARGER, BASEL, CH, vol. 17, no. 2, 1 March 2002 (2002-03-01), pages 83 - 89, XP009094962, ISSN: 1015-3837, DOI: 10.1159/000048014 *
DAVIS B H ET AL: "DETECTION OF FETAL RED CELLS IN FETOMATERNAL HEMORRHAGE USING A FETAL HEMOGLOBIN MONOCLONAL ANTIBODY BY FLOW CYTOMETRY", IMMUNOHEMATOLOGY, AMERICAN RED CROSS, WASHINGTON, DC, US, vol. 38, 1 August 1998 (1998-08-01), pages 749 - 756, XP001037503, ISSN: 0894-203X *
E. CHAMBERS ET AL: "Comparison of haemoglobin F detection by the acid elution test, flow cytometry and high-performance liquid chromatography in maternal blood samples analysed for fetomaternal haemorrhage", TRANSFUSION MEDICINE, vol. 22, no. 3, 20 March 2012 (2012-03-20), GB, pages 199 - 204, XP055524748, ISSN: 0958-7578, DOI: 10.1111/j.1365-3148.2012.01143.x *
HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495
OSBOURN ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 778
POLJAK, R. J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123
RALPH M. BOHMER ET AL: "Identification of fetal nucleated red cells in co-cultures from fetal and adult peripheral blood: differential effects of serum on fetal and adult erythropoiesis", PRENATAL DIAGNOSIS, vol. 19, no. 7, 1 July 1999 (1999-07-01), GB, pages 628 - 636, XP055525195, ISSN: 0197-3851, DOI: 10.1002/(SICI)1097-0223(199907)19:7<628::AID-PD601>3.0.CO;2-# *
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546

Similar Documents

Publication Publication Date Title
Andrews et al. N-glycolylneuraminic acid and N-acetylneuraminic acid define feline blood group A and B antigens
AU652598B2 (en) Diagnostic method for detecting the rupture of fetal membranes and test kit employing the method
AU2008334976B2 (en) Compositions and methods for early pregnancy diagnosis
US5514557A (en) Method and kit for detecting antibodies specific for HLA and/or platelet glycoproteins
Chapman et al. Distribution of developmentally regulated hemoglobins in embryonic erythroid populations
ES2895512T3 (es) Diluyente de reactivos
JP2789306B2 (ja) インスリン様成長因子の免疫学的測定方法ならびにインスリン様成長因子測定用キット
JP7508494B2 (ja) ヘモグロビンの測定試薬、測定キット及び測定方法
DK174032B1 (da) Sæt samt fremgangsmåde til immunometrisk dosering, der kan anvendes på hele celler
EP2006685A1 (fr) Kit de réactif pour la réaction d&#39;agglutination immune et procédé pour tester l&#39;antigène
US20140024057A1 (en) Systems and methods for detecting animal pregnancy
US5514598A (en) Prenatal detection of meconium
ES2284911T3 (es) Determinacion y cuantificacion de poblaciones de globulos rojos en muestras.
WO2019060687A1 (fr) Procédé de détermination de globules rouges foetaux dans une circulation maternelle par cytométrie de flux
JP3490715B2 (ja) ヘモグロビン前進性グルコシル化終末産物の検出方法
US8383410B2 (en) C4d/C4b standard for quantitative flow cytometry of humoral transplant rejection
US20120202297A1 (en) Gender determination method
JPS6022295B2 (ja) 赤血球凝集試験用水性溶媒
RU2780565C2 (ru) Способ определения членов семейства s100 связывающих кальций белков посредством иммунотурбидиметрии
JP2000206117A (ja) ヒトヘモグロビンの安定化方法
JP3995316B2 (ja) ホルモンレセプターに対する自己抗体の測定による癌の検出方法
JPS5926065A (ja) ヒト尿カリクレイン測定用試薬
WO2022013894A1 (fr) Trousse de diagnostic visuel de la grossesse chez le bétail et son procédé de détection
RU2319152C2 (ru) Способ диагностики токсоплазменной инфекции у детей
JPH06324046A (ja) 悪性腫瘍の検出方法及びキット

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18786502

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18786502

Country of ref document: EP

Kind code of ref document: A1